Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,458
Out of 4,814 analysts
11
Total ratings
n/a
Success rate
-35.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $30.40 | +80.92% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.90 | +321.05% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $9.70 | +260.82% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $6.83 | +163.74% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.15 | +122.58% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $5.50 | +9.09% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.09 | +443.48% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $62.24 | -64.65% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $16.34 | +46.88% | 1 | Dec 19, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | $10 | $10.14 | -1.38% | 1 | Oct 26, 2021 |
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $30.40
Upside: +80.92%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.90
Upside: +321.05%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $9.70
Upside: +260.82%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $6.83
Upside: +163.74%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.15
Upside: +122.58%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $5.50
Upside: +9.09%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.09
Upside: +443.48%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $62.24
Upside: -64.65%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $16.34
Upside: +46.88%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $10.14
Upside: -1.38%